A culture of adaptability and round-the-clock support. Agile technology transfers and a steadfast commitment to quality. Sustainable, strategic alliances that foster lasting partnerships.
These are the core attributes that biopharma companies, large and small, seek in a trusted manufacturing partner. From analytical agility and scalable capacity to acting as a seamless extension of the client’s team, the ability to adapt systems and processes in lockstep with evolving needs and regulatory requirements is fundamental to building long-term, resilient partnerships.
At a leading contract development and manufacturing organization (CDMO), operational excellence must be rooted in a company-wide commitment to delivering high-quality products on time. While the industry works to expand access to biomedicines worldwide, quality and reliability should remain central to the organization’s mission of providing end-to-end development and manufacturing services for complex modalities, shaping the therapeutic landscape.
Maximizing opportunities for meaningful collaboration
Today’s biopharma innovators look beyond transactional relationships to development and manufacturing partners capable of long-term collaboration. As therapeutic pipelines and regulatory frameworks continue to evolve, transparent communication is essential to transforming each interaction into a foundation for trust and continuity.
The right CDMO partner listens to and responds to client needs, fostering a positive feedback loop through flexible production schedules. It offers 24/7 support, the strategic configuration of manufacturing facilities, and the creation of company-wide campaigns. The organizational culture is where the persistent search for innovative solutions is the norm, there is no room for complacency, and continuous improvement permeates every department.
Track record of partnership: Balancing thoroughness with speed
A 99% batch success rate is just the beginning. Digitalization and AI-powered automation efforts reflect a company-wide mindset that focuses on speed, precision, and scale. Digital twin technology, which enables clients to monitor their project data in real time, leverages computational fluid dynamics to provide insights into cell growth, nutrient consumption, hydrodynamic behavior, and other critical bioreactor variables. Through such bioprocess solutions, a reliable and flexible CDMO works alongside its partners to streamline technology transfers and optimize scale-up.
Proactive risk assessments contribute to an in-depth understanding of clients’ projects and their unique requirements, balancing meticulous planning with agile execution in technology transfer. Driven by a commitment to maximizing efficiency, dedicated experts — from manufacturing and operations to project management and quality — make possible an industry-leading six-month transfer from kick-off to the engineering run.
Setting the agenda for excellence
Samsung Biologics has repeatedly demonstrated agility, most notably with its three-month technology transfer during the COVID-19 pandemic, which enabled the supply of biomedicines worldwide. As a result, the CDMO has established itself as a strategic partner. Its reputation has helped secure long-term, multi-product contracts and expanded its influence within the global biomanufacturing ecosystem. Its story is defined not only by infrastructure and scale but also by a commitment that evolves with — and ahead of — industry needs.
To further cater to client needs for diverse modalities, Samsung Biologics has expanded its service scope to include bioconjugation and end-to-end antibody-drug conjugate (ADC) services, as well as drug discovery and screening through Samsung Organoids. The CDMO’s purpose-built ADC facility streamlines the coordination of conjugation development with full-scale manufacturing. And through the company’s research services, clients can address challenges that may arise during the drug discovery phase, not only enhancing clinical success rates but also creating new possibilities in personalized medicine. By supporting clients through the drug lifecycle from start to finish with comprehensive therapeutic analysis, the CDMO adds value and builds on its track record of creating meaningful partnerships.
Looking ahead, Samsung Biologics is leveraging AI and digital infrastructure to transform biologics manufacturing. By integrating intelligent systems into every stage of the process, the company will continue to deliver operational efficiency while improving agility, ensuring compliance, and offering client-centric innovation. With a robust pipeline of projects, a growing base of strategic partnerships, and a reputation for quality and reliability, the CDMO is well-positioned to meet the complex and evolving therapeutic demands of the next decade. Its role extends beyond execution to strategic co-creation, where Samsung Biologics becomes an extension of each client’s team. As the sector continues to evolve, the company is not just keeping pace — it is actively setting the agenda for what biopharma excellence looks like.
Explore partnership opportunities and learn more at samsungbiologics.com/contact-us.
link